News & Events

News Releases

April 5, 2024

NGM Bio Announces Closing of Tender Offer

March 19, 2024

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

March 11, 2024

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results


October 17, 2022 at 5:00 AM PDT

June 29, 2022 from 11:00 AM to 12:30 PM EDT

Contact Information

investor relations

media relations